Solutions
Online Inquiry
Inquiry

Bispecific Antibody (BsAb) Development Platform

Bispecific antibodies (BsAb) have broad application prospects in the fields of tumor treatment and autoimmune diseases. With its advanced antibody development platform and mature mammalian cell expression platform, our company provides efficient and economical bispecific antibody production and expression services. We employ top experts and teams to provide you with a comprehensive and one-stop bispecific antibody development service for rare disease therapy research to meet all your needs.

Introduction to Bispecific Antibody

Bispecific antibodies are artificial antibodies containing two specific antigen-binding sites. They can build bridges between target cells and functional molecules and stimulate directed immune responses. They are a type of genetically engineered antibodies. The main preparation methods of bispecific antibodies include quadromas, chemical conjugation, and genetic recombination. Among them, the genetic recombination method is the most commonly used and most advanced preparation method. Due to their specificity and bifunctionality, bispecific antibodies have become a hot topic in the field of antibody engineering and have been explored for drug delivery, cancer immunotherapy, and Alzheimer's disease.

2-1-3-3 Bispecific Antibody (BsAb) Development Platform-1Fig.1 Timeline of historical bispecific antibody developments and clinical trials. (Li, H., et al., 2020)

BsAb Formats

The formats of BsAb can be broadly divided into immunoglobulin G (IgG)-like formats and non-IgG-like formats.

IgG-like formats Non-IgG-like formats
The IgG-like format retains the two Fab arms and one Fc region and has FC-mediated effector functions, such as complement-dependent cytotoxicity (CDC), antibody-dependent cell-mediated cytotoxicity (ADCC), and antibody-dependent cellular phagocytosis (ADCP). There are usually several preparation methods: The non-IgG-like format does not contain the Fc region. Its relative molecular mass is small, it can be expressed in prokaryotic cells, and it is easier to penetrate tissues and tumor cells to reach the target site. However, since it does not contain the Fc region of the antibody, it cannot mediate the corresponding biological function and its half-life is usually short. Common types of non-IgG-like formats include the following:
  • Triomabs
  • Knobs-into-holes
  • Crossmab
  • Ortho-Fab
  • DVD-Ig
  • Two-in-one
  • IgG-scFv
  • scFv2-Fc
  • BiTE
  • DART
  • TandAbs
  • bi-Nanobody

Our Services

With extensive experience and expertise in cell fusion or recombinant DNA technology, our company provides the production and expression of bispecific antibodies, such as bispecific T cell engagers, CrossMab, DVD-IgG, and Diabody, as well as bispecific antibodies preclinical research services. Bispecific antibody development services we can provide include but are not limited to:

BsAb Design

  • Target based BsAb design
  • MOA based BsAb design
  • Therapeutic area based BsAb design

BsAb Production

  • Gene synthesis and codon optimization
  • Vector construction
  • Expression and purification
  • QC analysis

BsAb Engineering

  • Bispecific IgGs development
  • BsAb fragments development
  • Bispecific fusion proteins development
  • BsAb conjugates development

Our Advantages

  • Cutting-edge technology and equipment
  • One-stop platform with an experienced team
  • Competitive pricing and fast turnaround time
  • Ability to customize products and services
  • Superior data quality and fast turnaround
  • Access to a diverse pool of talent

Project Workflow

2-1-3-3 Bispecific Antibody (BsAb) Development Platform-2

With many years of experience and a proven track record of quality, innovation, and customer support, our company provides comprehensive services for leading and emerging biopharmaceutical companies and scientific research institutions to develop bispecific antibodies for rare diseases. If you are interested in our services, please feel free to contact us for more details and quotation information of related services.

Reference

  • Li, H., et al. "Challenges and strategies for next-generation bispecific antibody-based antitumor therapeutics." Cellular & molecular immunology 17.5 (2020): 451-461.

All of our services and products are intended for preclinical research use only and cannot be used to diagnose, treat or manage patients.

Related Services

Copyright © Protheragen. All rights reserves.